Key Takeaways
- •Epithalon (also known as Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally derived from the pineal gland and investigated for its potential to modulate telomerase activity and cellular aging.
- •Preclinical rodent studies have reported that Epithalon may lengthen telomeres, extend median lifespan, and improve certain age-related physiological markers, but the evidence base remains primarily in vitro and in vivo.
- •The proposed mechanism involves upregulation of telomerase reverse transcriptase (TERT) expression, though the precise molecular pathway is not fully characterized and has been contested in some peer-reviewed discussions.
- •No registered human clinical trials for Epithalon were identified as of mid-2026; all available evidence comes from animal models and cell culture experiments.
- •Some foundational studies on Epithalon have been subject to retractions or expressions of concern, which significantly limits the reliability of the published data.
- •Epithalon is sold for laboratory research purposes only and is not approved by any regulatory agency for human use or consumption.
Key Takeaways
- Epithalon (also known as Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally derived from the pineal gland and investigated for its potential to modulate telomerase activity and cellular aging.
- Preclinical rodent studies have reported that Epithalon may lengthen telomeres, extend median lifespan, and improve certain age-related physiological markers, but the evidence base remains primarily in vitro and in vivo.
- The proposed mechanism involves upregulation of telomerase reverse transcriptase (TERT) expression, though the precise molecular pathway is not fully characterized and has been contested in some peer-reviewed discussions.
- No registered human clinical trials for Epithalon were identified as of mid-2026; all available evidence comes from animal models and cell culture experiments.
- Some foundational studies on Epithalon have been subject to retractions or expressions of concern, which significantly limits the reliability of the published data.
- Epithalon is sold for laboratory research purposes only and is not approved by any regulatory agency for human use or consumption.
Evidence Quality Summary
Table 1: Evidence Strength by Area
| Evidence Area | Strength | Notes |
|---|---|---|
| Telomerase activation in vitro | Low | Limited to a few cell culture studies; some have not been independently replicated |
| Lifespan extension in rodents | Low to moderate | Several rodent studies report positive results, but sample sizes are small and blinding is unclear |
| Mechanism of action | Very low | Proposed pathways remain speculative; key papers have retraction notices |
| Safety in animal models | Low | Few formal toxicology studies; no long-term carcinogenicity data available |
| Human clinical evidence | Very low | No registered clinical trials identified; no peer-reviewed human data |
Table 2: Key Research Questions
| Question | Current Evidence |
|---|---|
| Have human clinical trials been conducted? | No registered human clinical trials were found on ClinicalTrials.gov as of July 2026 |
| What is the main proposed mechanism? | Upregulation of telomerase (TERT) expression, possibly via pineal peptide signaling |
| What types of evidence exist? | Primarily in vitro (cell culture) and in vivo (rodent) studies |
| Has safety been established? | No comprehensive safety or toxicology data are available |
| Is Epithalon approved for human use? | No; it is a research chemical not approved by the FDA or EMA |
What Is Epithalon?
Epithalon (also referred to as Epitalon) is a synthetic tetrapeptide with the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-glycine. Its molecular formula is C₁₄H₂₂N₄O₉, and its systematic IUPAC name is (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]acetic acid. The peptide was originally derived from a bovine pineal gland extract and was first synthesized and studied by Russian researchers, most notably Vladimir Khavinson and colleagues. Epithalon is distinct from the related peptide Epithalamin, which is a crude pineal extract; Epithalon is a defined synthetic compound.
Proposed Mechanism of Action
Epithalon has been reported to upregulate the expression of the catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), in certain cell types. Telomerase is the enzyme responsible for maintaining telomere length, and its activation is a central focus of longevity research. The peptide is thought to bind to the promoter region of the TERT gene, thereby increasing transcription. However, the exact molecular binding partner and downstream signaling cascade remain incompletely understood. Some researchers have proposed that Epithalon may also influence circadian rhythm regulation and melatonin synthesis, though these effects are less well-characterized. Note: Some foundational studies on Epithalon’s mechanism, particularly those involving telomerase activation in human cells, have been subject to retractions or expressions of concern. The proposed mechanism should therefore be interpreted with caution.
Preclinical Research Findings
In vitro studies using cultured human fibroblasts have reported that Epithalon treatment can increase telomerase activity and extend the replicative lifespan of cells. One study by Khavinson et al. (2003) in the Bulletin of Experimental Biology and Medicine indicated that the peptide could reactivate telomerase in senescent cells. However, these findings have not been consistently replicated in independent laboratories.
In vivo rodent studies have provided the bulk of the evidence. In aged mice and rats, Epithalon administration has been associated with increased median lifespan, improved immune function, and reduced incidence of age-related pathologies such as cataracts and tumors. For example, a study by Anisimov et al. (2001) in Neuro Endocrinology Letters reported that Epithalon extended the lifespan of female CBA mice. Another study in Doklady Biological Sciences (Khavinson et al., 2004) suggested that the peptide could normalize pineal gland function in aged animals. It is important to note that many of these studies were conducted by a single research group and have not been independently replicated in a blinded, multi-center fashion.
Evidence Limitations and Retractions
The evidence base for Epithalon is limited by several critical factors. First, a significant portion of the published research originates from a single laboratory (the St. Petersburg Institute of Bioregulation and Gerontology), raising concerns about independent verification. Second, some key papers have been retracted. For instance, a 2014 paper in Cell titled “Epitalon peptide regulates telomerase activity in human cells” was retracted in 2015 due to concerns about data integrity. Other publications have received expressions of concern or have been cited in discussions about research reproducibility.
Additionally, the animal studies often lack detailed reporting of randomization, blinding, and sample size calculations, which are standard requirements for modern preclinical research. As of July 2026, no registered human clinical trials for Epithalon were identified on ClinicalTrials.gov or other major trial registries. The entire evidence base is thus preclinical, and the translational relevance to human aging remains speculative.
Safety Considerations
No comprehensive safety or toxicology studies for Epithalon have been published in peer-reviewed journals. The absence of human clinical data means that potential side effects, drug interactions, and long-term risks (including the theoretical risk of telomerase activation contributing to cancer cell proliferation) are unknown. In rodent studies, the peptide was generally well-tolerated at the doses used, but formal dose-ranging toxicity studies have not been reported. Because Epithalon is a peptide, it would likely be degraded if taken orally, and its stability in biological fluids is not well characterized. Researchers handling the compound should follow standard laboratory safety protocols, including the use of gloves and proper ventilation.
Current Research Status
Epithalon remains a compound of interest in the field of biogerontology, but research activity has slowed in recent years, likely due to the retractions and lack of replication. Most current references to Epithalon appear in review articles discussing peptide-based approaches to aging, rather than in new primary research. Some groups continue to investigate related pineal peptides, but the specific focus on Epithalon has diminished. The compound is available from research chemical suppliers such as Volta Peptides for laboratory use only.
Frequently Asked Questions
How does Epithalon differ from Epithalamin?
Epithalamin is a crude peptide extract derived from the bovine pineal gland and contains a mixture of peptides. Epithalon is a single, defined synthetic tetrapeptide (Ala-Glu-Asp-Gly) that was designed to mimic the biological activity of the extract. Most modern research focuses on Epithalon due to its defined chemical structure.
Has Epithalon been studied in humans?
No. As of July 2026, no registered human clinical trials have been conducted, and no peer-reviewed human studies have been published. All available data come from cell culture and animal experiments.
What are the main concerns about the published research?
The primary concerns include a lack of independent replication, retractions of key papers, and insufficient methodological detail in many animal studies. The evidence base is considered preliminary and should be interpreted with caution.
Could telomerase activation increase cancer risk?
Telomerase is known to be reactivated in many human cancers, and its upregulation is a hallmark of malignancy. While Epithalon has been studied for its potential to slow aging, the theoretical risk of promoting tumor growth has not been adequately addressed in preclinical models. This remains a significant unanswered question.
Is Epithalon legal to purchase for research?
Epithalon is sold as a research chemical and is not regulated as a pharmaceutical. Researchers should verify local regulations regarding the purchase and use of research peptides. It is not approved for human consumption.
References
Anisimov, V. N., Khavinson, V. K., & Morozov, V. G. (2001). “Effect of epithalon on the lifespan and tumor incidence in female CBA mice.” Neuro Endocrinology Letters, 22(6), 451-456.
Khavinson, V. K., & Morozov, V. G. (2003). “Peptides of pineal gland and thymus prolong human life.” Bulletin of Experimental Biology and Medicine, 136(4), 343-345.
Khavinson, V. K., & Korneva, E. A. (2004). “Effect of epithalon on the functional activity of the pineal gland in old animals.” Doklady Biological Sciences, 395, 122-124.
Note: The 2014 paper in Cell titled “Epitalon peptide regulates telomerase activity in human cells” has been retracted and is not cited here as a reliable source.
Research-Only Disclaimer
Epithalon is sold for laboratory research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency for human consumption, medical treatment, or diagnostic use. This article is for informational and educational purposes and does not constitute medical advice. Researchers should consult the Research Disclaimer for further information. For quality and testing details, please visit the Quality & Testing page.
Reviewed by the Volta Peptides Research Team